OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer ...
NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that the Japanese Patent Office has issued the notice of ...
CAMBRIDGE, Mass. & ROCKVILLE, Md.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), ...
ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a ...
OSE Pharma (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE), an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration Phase 3 study, and Effimune, a ...
Harnessing the power of the immune system to destroy cancer has dominated the biotech industry over the past decade. And for good reason: CAR-T therapies, checkpoint inhibitors, oncolytic viruses, and ...
Barely a year after pulling in $125 million to advance a pair of T-cell therapies, TCR2 Therapeutics is looking to raise up to $80 million in an IPO. The Cambridge, Massachusetts-based biotech plans ...
The annual meeting of the American Society of Hematology (ASH), now wrapping up in Atlanta, has generated a lot of excitement about immuno-oncology treatments like Bluebird Bio and Celgene’s ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of its universal cancer immunogenomics platform, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback